Abeona Therapeutics Announces Publication of Positive Long-Term Data from Phase 1/2a Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
October 15, 2019 09:15 ET
|
Abeona Therapeutics Inc.
Sustained wound healing and favorable safety profile observed at three years post-treatment Durable wound healing in large, disabling, chronic wounds EB-101 associated with long-term molecular...
Abeona Therapeutics Announces Strategic Review
September 03, 2019 09:00 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it has retained Jefferies...
Abeona Therapeutics Reports Second Quarter 2019 Financial Results and Business Updates
August 09, 2019 16:15 ET
|
Abeona Therapeutics Inc.
Five patients with MPS IIIB treated in the Transpher B Study of ABO-101 gene therapy Positive interim MPS IIIA data showed preservation of neurocognitive development in youngest patients with robust...
Abeona Therapeutics Reports First Quarter 2019 Financial Results and Business Highlights
May 10, 2019 16:15 ET
|
Abeona Therapeutics Inc.
CMC work completed in advance of EB-101 Phase 3 VITAL™ trial expected to begin mid-2019 IND submitted for ABO-202 in CLN1 disease Investor conference call on Tuesday, May 14 at 10:00 a.m. ET NEW...
Abeona Therapeutics Announces Presentation of EB-101 Data at Society for Investigative Dermatology Annual Meeting
May 08, 2019 08:30 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 08, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that long-term follow up data...
Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
May 07, 2019 16:15 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, May 07, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced its participation in the...
Abeona Therapeutics Appoints João Siffert, M.D. Chief Executive Officer
February 11, 2019 16:05 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and gene therapies for...
Abeona Therapeutics Details Pathway for Advancing Lead Clinical Programs and Unveils New Cystic Fibrosis Program Born from Next Generation AIM™ Vector Platform at 2018 R&D Day
December 06, 2018 12:30 ET
|
Abeona Therapeutics Inc.
EB-101 pivotal trial for Recessive Dystrophic Epidermolysis Bullosa planned for mid-2019 enrollment Expanding Phase I/II study of ABO-102 for Sanfilippo syndrome type A (MPS IIIA) Novel AIMTM AAV...
Abeona Announces Participation at the Jefferies 2018 London Healthcare Conference
November 13, 2018 08:45 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Nov. 13, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene...
Abeona Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights
November 09, 2018 16:20 ET
|
Abeona Therapeutics Inc.
Investor Conference Call on Monday, November 12th at 10:00 a.m. ET NEW YORK and CLEVELAND, Nov. 09, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage...